fresh no ads
Pfizer and AZ COVID-19 jabs 'highly effective' in elderly — UK study | Philstar.com
^

Health And Family

Pfizer and AZ COVID-19 jabs 'highly effective' in elderly — UK study

Agence France-Presse
Pfizer and AZ COVID-19 jabs 'highly effective' in elderly — UK study
In this file photo taken on November 23, 2020 is pictured a bottle reading "Vaccine Covid-19" next to US pharmaceutical company Pfizer and German biotechnology company BioNTech logos on November 23, 2020. Pharma companies Pfizer and BioNTech on December 1, 2020 filed for European approval for their coronavirus vaccine, following in the footsteps of competitor Moderna, while the OECD predicted the world economy would bounce back to pre-pandemic levels by late 2021.
AFP / Joel Saget

LONDON, United Kingdom — The Pfizer and Oxford-AstraZeneca vaccines have been "highly effective" in reducing coronavirus infections and severe illness among elderly people in Britain, with a more than 80 percent reduction in hospitalisation, official data showed Monday.

In the over 80s, a single dose of either vaccine is more than 80 percent effective at preventing hospitalisation around three to four weeks after the jab, according to a Public Health England real-world study that has gathered data since January.

The study comes as France and Germany consider reversing their refusal to authorise the AstraZeneca vaccine for people over 65 due to concerns of its efficacy.

British Health Secretary Matt Hancock hailed the new study as "extremely good news".

"The detailed data show that the protection that you get from catching COVID 35 days after a first jab is even slightly better for the Oxford jab than for Pfizer," he added.

Both vaccines "are highly effective in reducing COVID-19 infections among older people aged 70 years and over," added the study.

The Pfizer jab has offered protection against catching the disease of between 57 and 61 percent after the first dose, with the AstraZeneca vaccine offering protection of between 60 and 73 percent, according to the study.

"This adds to growing evidence showing that the vaccines are working to reduce infections and save lives," said Mary Ramsay, Public Health England's head of immunisation.

"It is important to remember that protection is not complete and we don't yet know how much these vaccines will reduce the risk of you passing COVID-19 onto others," she added.

Britain has given the first dose of one of the two vaccines to more than 20 million people as part of a mass rollout that is seen as vital in taming one of the world's worst outbreaks, which has so far claimed almost 123,000 lives.

Asked about the scepticism in some European countries about the effectiveness of the AstraZeneca vaccine, Jonathan Van-Tam, deputy chief medical officer for England, said the results "vindicated" Britain's approach.

"I think in time the data emerging from the programme will speak for itself and other countries will doubtless be very interested in it," he said.

Britain announced another 104 fatalities on Monday, and 5,455 new cases -- almost half the number recorded last Monday.

The number of COVID admissions to intensive care units among people aged over 80 has dropped to single figures in the last two weeks, Hancock said.

Britain will next week begin to unwind its third lockdown, with a plan for life to return to normal by the end of June.

The latest results highlighted the importance of everyone getting vaccinated, said Van-Tam.

"It shows us, gives us those first glimpses, of how if we are patient, and we give this vaccine programme time to have its full effect, it is going to hopefully take us into a very different world. In the next few months.

vuukle comment

2019 N-COV

COVID-19 VACCINE

NOVEL CORONAVIRUS

Philstar
x
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with